ABBV-155 is an antibody drug conjugate linking a BCL-XL inhibitor with an anti-B7H3 antibody, thereby specifically targeting B7H3-expressing cancer cells and minimizing platelet destruction. The gene discussed is BCL2L1; the disease is cancer.